cache

Home cache
  • Next Post
  • Previous Post

cache

David Dornan, PhD

/ Uncategorized

Share the Post

About the Author

Related Posts

Phase I results from a phase 1/2 multi-center study of nab-sirolimus combined with mFOLFOX6+bevacizumab (FB) as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss
Phase II Trial of nab-sirolimus in Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update
nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program
Aadi Bioscience Appoints Brendan Delaney as Chief Operating Officer
Aadi Bioscience to Participate in Upcoming Investor Conferences
Aadi Bioscience Launches its Phase 2 Registration Trial for ABI-009PEComa
A phase I/II multicenter study of ABI-009 (nab-sirolimus) combined with FOLFOX and bevacizumab as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss

Comments

Comments are closed.

  • Next Post
  • Previous Post